REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Clinical trials for REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (lymphoma, multiple myeloma, or histiocytic/dendritic cell tumors) that have come back or not responded to prior treatment. The main goal is to fi…
Matched conditions: REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 07:51 UTC
-
Precision drug targets rare RET mutations in Kids' cancers
Disease control OngoingThis study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. Participants have advanced solid tumors, lymphomas, o…
Matched conditions: REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:44 UTC
-
New hope for kids with hard-to-treat cancers: targeted pill attacks faulty gene pathway
Disease control OngoingThis study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …
Matched conditions: REFRACTORY HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC